RNA -based blood test identifies parkinson before the appearance of symptoms

Researchers have developed a simple and profitable blood test capable of detecting Parkinson’s disease long before the emergence of symptoms, comparing the current diagnostic state of neurodegenerative diseases to the fight against cancer 50 years ago – when most cases were identified too late for effective treatment.

The test quantifies specific RNA fragments in the blood, focusing on a repetitive RNA sequence which accumulates in Parkinson patients and a parallel drop in mitochondrial RNA, which deteriorates as the disease progresses.

By measuring the relationship between these biomarkers, the test offers a very precise, non -invasive, fast and affordable diagnostic tool, giving hope for early interventions and treatments that could change the course of the disease.

The diagnosis of neurodegenerative diseases is nowadays at the level that the diagnosis of cancer was 50 years ago: the disease is identified when most relevant neurons are already dead, and it is therefore too late to cure.

To solve this problem, researchers from the Hebrew University of Jerusalem have unveiled a blood test which could revolutionize an early diagnosis of Parkinson’s disease (PD), paving the way for timely interventions and improving patient results.

The study, published in Aging of natureIntroduce a new approach to detect MP in the early stages thanks to the analysis of transfer RNA fragments (TRFS).

Traditionally neglected in Parkinson’s research, TRF (Transfer RNA fragments) are small RNA molecules that can reveal significant changes in the body linked to neurodegeneration.

The researchers, led by PH.D. The student Nimrod Madrer, under the supervision of Professor Hermona Soreq at the Edmond and Lily Safra Center for Brain Sciences (ELSC) and at the Alexander Silberman Institute of Life Sciences, at Hebrew University, in collaboration with Dr Iddo Paldor specific to the PD bearing (RGTTCRA-TRFS) and a decrease in mitochondrias (MT-TRF).

By measuring the relationship between these biomarkers, the new test can distinguish patients from the pre -Sactatic Parkinson from healthy witnesses with a precision exceeding that of existing clinical diagnostic tools.

“This discovery represents major progress in our understanding of Parkinson’s disease and offers a simple and minimally invasive blood test as an early diagnostic tool,” said Professor Hermona Soreq. “By focusing on TRF, we have opened a new window on the molecular changes that occur in the early stages of the disease.”

The test uses a simple and simple QPCR dosage, measuring the relationship between the repeated short pattern and an exemplary mitochondrial sequence, which makes it profitable and accessible for use in a wide range of health environments.

In the trials involving samples of several international cohorts, in particular the initiative of Parkinson’s progression markers, the test carried out diagnostic accuracy of 86%, considerably surpassing traditional clinical notation methods. In addition, the study revealed that the RGTTCRA-TRF levels decrease after deep cerebral stimulation, moreover connecting these RNA fragments to the mechanisms of the disease and the responses of the treatment.

The main researcher Nimrod Madrer stressed the importance of early detection, noting that Parkinson’s disease is often diagnosed only after significant brain lesions have occurred. “This test has the potential to relieve the uncertainty that patients and clinicians face, offering a reliable and rapid method to identify the disease in its first stages,” said Madrer.

The results were published under the requests for an American provisional patent, and large -scale diagnostic tests provided broader clinical validation. This research represents an important step in the fight against Parkinson’s disease, offering new hope to millions of people around the world.